

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Regado Biosciences, Inc.		05/25/2011	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	MidCap Financial SBIC, LP		
Street Address:	7735 Old Georgetown Road		
Internal Address:	Suite 400		
City:	Bethesda		
State/Country:	MARYLAND		
Postal Code:	20814		
Entity Type:	LIMITED PARTNERSHIP: DELAWARE		
PROPERTY NUMBERS Total: 6			
Property Type	Number	Word Mark	
Serial Number:	77658131	REGADO BIOSCIENCES	
Serial Number:	77658125	REGADO BIOSCIENCES	
Serial Number:	77655445	WE TAKE SCIENCE TO HEART	
Serial Number:	77658139	REGADO	
Serial Number:	77658108	REGADO	
Serial Number:	77652298	TAKING SCIENCE TO HEART	
CORRESPONDENCE DATA			
Fax Number:	(404)443-5697		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	404-443-5742		
Email:	lallen@mcguirewoods.com		
Correspondent Name:	Lizzie Garner, Esq.		
Address Line 1:	McGuireWoods LLP		
Address Line 2:	1230 Peachtree Street, N.E., Suite 2100		
Address Line 4:	Atlanta, GEORGIA 30309		

OP \$165.00 77658131

ATTORNEY DOCKET NUMBER:	2061695-0001 (REGADO)
NAME OF SUBMITTER:	Latosha E. Allen
Signature:	/Latosha E. Allen/
Date:	05/27/2011

Total Attachments: 14

source=Regado - IP Security Agreement #page1.tif
source=Regado - IP Security Agreement #page2.tif
source=Regado - IP Security Agreement #page3.tif
source=Regado - IP Security Agreement #page4.tif
source=Regado - IP Security Agreement #page5.tif
source=Regado - IP Security Agreement #page6.tif
source=Regado - IP Security Agreement #page7.tif
source=Regado - IP Security Agreement #page8.tif
source=Regado - IP Security Agreement #page9.tif
source=Regado - IP Security Agreement #page10.tif
source=Regado - IP Security Agreement #page11.tif
source=Regado - IP Security Agreement #page12.tif
source=Regado - IP Security Agreement #page13.tif
source=Regado - IP Security Agreement #page14.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the 25th day of May, 2011 by and between MIDCAP FINANCIAL SBIC, LP, a Delaware limited liability company ("Agent") and REGADO BIOSCIENCES, INC. ("Grantor").

RECITALS

A. The Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Loan Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.

[Signature page follows.]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

REGADO BIOSCIENCES, INC.

120 Mountain View Blvd.
Basking Ridge, NJ 07920
Attn: Chris Sauter

By: 
Title: VP - Finance

AGENT:

Address of Agent:

MIDCAP FINANCIAL SBIC, LP
By: MIDCAP FINANCIAL SBIC, GP

7735 Old Georgetown Road, Suite 400
Bethesda, Maryland 20814
Attn: Portfolio Management- Life Sciences

By: _____
Title: _____

REGADO BIOSCIENCES, INC.
INTELLECTUAL PROPERTY SECURITY AGREEMENT
SIGNATURE PAGE

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

REGADO BIOSCIENCES, INC.

By: _____

Title: _____

Attn: _____

AGENT:

Address of Agent:

MIDCAP FINANCIAL SBIC, LP

By: **MIDCAP FINANCIAL SBIC, GP**

7735 Old Georgetown Road, Suite 400

Bethesda, Maryland 20814

Attn: Portfolio Management- Life Sciences

By: _____ 

Title: Authorized Signatory

Josh Groman
Managing Director

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME									
10815-8001	ATL No. 10815-105002	US	Expired	60/235,654	26-Sep-00				
10815-8001.US00	ATL No. 10815-105005	US	Granted	09/963,827	26-Sep-01	2003-0175703	18-Sep-03	7,312,325	25-Dec-07
10815-8001.US01	ATL No. 10815-105017	US	Granted	11/925,641	26-Oct-07	2008-0182809	31-Jul-08	7,812,001	12-Oct-10
10815-8001.US02	ATL No. 10815-105018	US	Granted	11/925,645	26-Oct-07	2008-0221053	11-Sep-08	7,741,307	22-Jun-10
10815-8001.US03	ATL No. 10815-105019	US	Granted	11/925,648	26-Oct-07	2008-0207546	28-Aug-08	7,776,836	17-Aug-10
10815-8001.US04	ATL No. 10815-105020	US	Granted	11/925,651	26-Oct-07	2008-0200413	21-Aug-08	7,858,591	28-Dec-10
10815-8001.US05	ATL No. 10815-105021	US	Granted	11/936,015	06-Nov-07	2009-0163429	25-Jun-09	7,776,837	17-Aug-10
10815-8001.US06	ATL No. 10815-105020	US	Pending	12/971,695	17-Dec-10				
10815-8001.WO00	ATL No. 10815-105006	PCT	National	PCT/US01/30004	26-Sep-01	WO/2002/026932	04-Apr-02		
10815-8001.AU00	ATL No. 10815-105006 AU	AU	Granted	2001296305	26-Sep-01			2001296305	20-Mar-08
10815-8001.AU01	ATL No. 10815-105006 AU	AU	Pending	2007201745	26-Sep-01				
10815-8001.AU02	NA	AU							
10815-8001.CA00	ATL No. 10815-105006 CA	CA	Pending	2,425,208	26-Sep-01				
10815-8001.EP00	ATL No. 10815-105006 EP	EP	Published	01977167.4	26-Sep-01	1330544	30-Jul-03		
10815-8001.EP01	ATL No. 10815-105006 EP	EP	Pending	10185481.8	26-Sep-01				
10815-8001.EP02	ATL No. 10815-105006 EP	EP	Pending	10185469.3	01-Oct-10				

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
MODULATORS OF PHARMACOLOGICAL AGENTS									
10815-8002	ATL No. 10815-105002	US	Expired	60/293,231	25-May-01				
10815-8002.US00	ATL No. 10815-105002	US	Expired	60/331,037	07-Nov-01				
10815-8002.US01	ATL No. 10815-105008	US	Granted	10/155,233	28-May-02	2003-0083294	01-May-03	7,300,922	27-Nov-07
10815-8002.US02	ATL No. 10815-105008	US	Published	11/789,992	26-Apr-07	2008-0051339	28-Feb-08		
10815-8002.US03	ATL No. 10815-105027	US	Published	12/637,467	14-Dec-09	2010-0249217	30-Sep-10		
10815-8002.WO00	ATL No. 10815-105004	PCT	National	PCT/US2002/16555	28-May-02	WO/2002/096926	05-Dec-02		
10815-8002.AT00	ATL No. 10815-105004 AT	AT	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.AU00	ATL No. 10815-105004 AU	AU	Granted	2002312059	28-May-02			2002312059	30-Apr-09
10815-8002.AU01	ATL No. 10815-105004 AU	AU	Pending	2009200036	28-May-02				
10815-8002.BE00	ATL No. 10815-105004 BE	BE	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.CA00	ATL No. 10815-105004 CA	CA	Pending	2,448,567	28-May-02				
10815-8002.CH00	ATL No. 10815-105004 CH	CH	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.CY00	ATL No. 10815-105004 CY	CY	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.DE00	ATL No. 10815-105004 DE	DE	Granted	02739409.7	28-May-02	1401853	31-Mar-04	P60237768.4-08	22-Sep-10
10815-8002.DK00	ATL No. 10815-105004 DK	DK	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.EP00	ATL No. 10815-105004 EP	EP	Regional	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.EP01	ATL No. 10815-105004 EP	EP	Published	09156205.8	28-May-02	2070939	17-Jun-09		
10815-8002.EP02	ATL No. 10815-105004 EP	EP	Pending	10181597.5	28-May-02				
10815-8002.ES00	ATL No. 10815-105004 ES	ES	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.FI00	ATL No. 10815-105004 FI	FI	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.FR00	ATL No. 10815-105004 FR	FR	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.GB00	ATL No. 10815-105004 GB	GB	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
10815-8002.GR00	ATL No. 10815-105004 GR	GR	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.HK00	ATL No. 10815-105004 HK	HK	Published	09111516.3	09-Dec-09	1131623A	29-Jan-10		
10815-8002.IE00	ATL No. 10815-105004 IE	IE	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.IL00	ATL No. 10815-105004 IL	IL	Granted	159053	28-May-02	159053			
10815-8002.IN00	ATL No. 10815-105004 IN	IN	Granted	02209/DELNP/2003	28-May-02			221070	16-Jun-08
10815-8002.IN01	ATL No. 10815-105004 IN	India	Pending	3071/DELNP/2008	28-May-02				
10815-8002.IN02	ATL No. 10815-105004 IN	IN	Pending	3078/DELNP/2008	15-Apr-08				
10815-8002.IT00	ATL No. 10815-105004 IT	IT	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.JP00	ATL No. 10815-105004 JP	JP	Published	2003500105	28-May-02	2005502596	27-Jan-05		
10815-8002.JP01	ATL No. 10815-105004 JP	JP	Published	200968055	19-Mar-09	2009185035	20-Aug-09		
10815-8002.KR00	ATL No. 10815-105004 KR	KR	Abandoned	1020037015418	28-May-02				
10815-8002.LU00	ATL No. 10815-105004 LU	LU	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.MC00	ATL No. 10815-105004 MC	MC	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.NL00	ATL No. 10815-105004 NL	NL	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.PT00	ATL No. 10815-105004 PT	PT	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.SE00	ATL No. 10815-105004 SE	SE	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10
10815-8002.SG00	ATL No. 10815-105004 SG	SG	Abandoned	200307031-5	28-May-02				
10815-8002.SG01	ATL No. 10815-105004 SG	SG	Published	200702457-3	28-May-02	157961	29-Jan-10		
10815-8002.TR00	ATL No. 10815-105004 TR	TR	Granted	02739409.7	28-May-02	1401853	31-Mar-04	1401853	22-Sep-10

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
IMPROVED MODULATORS OF COAGULATION FACTORS									
10815-8003	ATL No. 10815-105003	US	Form Filed	60/564,873	22-Apr-04				
10815-8003.US00	ATL No. 10815-105003	US	Granted	11/113,378	22-Apr-05	2006-0040881	23-Feb-06	7,304,041	04-Dec-07
10815-8003.US01	ATL No. 10815-105003	US	Granted	11/821,183	22-Jun-07	2008-0153769	26-Jun-08	7,723,315	25-May-10
10815-8003.US02	ATL No. 10815-105037	US	Abandoned	12/729,968	23-Mar-10				
10815-8003.US03	ATL No. 10815-105037	US	Published	12/758,565	12-Apr-10	US-2010-0197900	05-Aug-10		
10815-8003.WO00	ATL No. 10815-105003	PCT	National	PCT/US2005/013926	22-Apr-05	WO/2005/106042	10-Nov-05		
10815-8003.AU00	ATL No. 10815-105003 AU	AU	Granted	2005238490	22-Apr-05			2005238490	
10815-8003.BR00	ATL No. 10815-105003 BR	BR	Published	PI0508931-0	22-Apr-05		14-Aug-07		
10815-8003.CA00	ATL No. 10815-105003 CA	CA	Pending	2,563,176	22-Apr-05				
10815-8003.CN00	ATL No. 10815-105003 CN	CN	Published	200580019913.7	22-Apr-05	1980947	13-Jun-07		
10815-8003.EP00	ATL No. 10815-105003 EP	EP	Published	05740895.7	22-Apr-05	1745062	24-Jan-07		
10815-8003.IL00	ATL No. 10815-105003 IL	IL	Pending	178564	22-Apr-05				
10815-8003.IN00	ATL No. 10815-105003 IN	IN	Pending	6960/DELNP/2006	22-Apr-05				
10815-8003.JP00	ATL No. 10815-105003 JP	JP	Published	2007509694	22-Apr-05	2007534324	29-Nov-07	4718541	
10815-8003.KR00	ATL No. 10815-105003 KR	KR	Published	1020067024518	22-Apr-05	2007-0031907	20-Mar-07		
10815-8003.SG00	ATL No. 10815-105003 SG	SG	Granted	200607333-2	22-Apr-05			126609	30-Apr-09
108015-8003.SG01	ATL No. 10815-105003 SG	SG	Abandoned	200902764-0	22-Apr-05				
MODULATORS OF COAGULATION FACTORS WITH ENHANCED STABILITY									
10815-8004	ATL No. 10815-105013	US	Expired	60/725,509	11-Oct-05				
10815-8004.US00	ATL No. 10815-105010	US	Granted	11/546,190	11-Oct-06	US-2008-0125383-A1	29-May-08	7,531,524	12-May-09
10815-8004.US01	ATL No. 10815-105012	US	Abandoned	11/605,712	27-Nov-06	2007-0105809	10-May-07		

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
ADMINISTRATION OF THE REGI ANTICOAGULATION SYSTEM									
10815-8005	ATL No. 10815-105011	US	Expired	60/808,987	26-May-06				
10815-8005.US00	ATL No. 10815-105011	US	Expired	60/847,809	27-Sep-06				
10815-8005.US01	ATL No. 10815-105011	US	Expired	60/865,352	10-Nov-06				
10815-8005.US02	ATL No. 10815-105011	US	Published	11/805,950	25-May-07	US-2009-0048193	19-Feb-09		
10815-8005.WO00	ATL No. 10815-105011	PCT	National	PCT/US2007/012625	25-May-07	WO/2007/140000	06-Dec-07		
10815-8005.EP00	ATL No. 10815-105011 EP	EP	Published	07815043.0	25-May-07	2026653	25-Feb-09		
108015-8005.IN00	ATL No. 10815-105011 IN	IN	Pending	07142/CHENP/2008	25-May-07				
10815-8005.AU00	ATL No. 10815-105011 AU	AU	Pending	2007267801	25-May-07				
10815-8005.BR00	ATL No. 10815-105011 BR	BR	Pending	PI0712473.2	25-May-07				
10815-8005.CA00	ATL No. 10815-105011 CA	CA	Pending	2,653,313	25-May-07				
10815-8005.CN00	ATL No. 10815-105011 CN	CN	Published	200780019405.8	25-May-07	101453891	10-Jun-09		
10815-8005.HK00	ATL No. 10815-105011 HK	HK	Published	09107197.7	28-Aug-09	1129540A	04-Dec-09		
10815-8005.IL00	ATL No. 10815-105011 IL	IL	Pending	194991	25-May-07				
10815-8005.JP00	ATL No. 10815-105011 JP	JP	Published	2009-512183	25-May-07	2009-538325	05-Nov-09		
10815-8005.KR00	ATL No. 10815-105011 KR	KR	Published	1020087030333	25-May-07	2009-0015118	11-Feb-09		
10815-8005.RU00	ATL No. 10815-105011 RU	RU	Pending	2008151758	25-May-07				
10815-8005.SG00	ATL No. 10815-105011 SG	SG	Pending	200808325-5	25-May-07				
10815-8005.UA00	ATL No. 10815-105011 UA	UA	Pending	200814934	25-May-07				
10815-8005.ZA00	ATL No. 10815-105011 ZA	ZA	Pending	2008/09575	25-May-07				

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
NUCLEIC ACID BINDING COMPOUNDS AS MODULATORS OF PHARMACOLOGICAL AGENTS									
10815-8006.US00	ATL No. 10815-105015	US	Pending	12/115,322	05-May-08				
10815-8006	ATL No. 10815-105001	US	Expired	60/927,399	03-May-07				
STEADY-STATE SUBCUTANEOUS ADMINISTRATION OF APTAMERS									
10815-8007	ATL No. 10815-105016	US	Expired	60/999,080	16-Oct-07				
10815-8007.US00	ATL No. 10815-105016	US	Abandoned	12/252,994	16-Oct-08	2009-0163437	25-Jun-09		
10815-8007.WO00	ATL No. 10815-105016	PCT	Abandoned	PCT/US2008/080187	16-Oct-08	WO2009/052301	23-Apr-09		
ACTIVELY REVERSIBLE INHIBITORS OF PLATELET PURINERGIC RECEPTORS									
10815-8008	ATL No. 10815-105014	US	Expired	60/901,060	12-Feb-07				
10815-8008.US00	ATL No. 10815-105014	US	Expired	60/901,670	13-Feb-07				
10815-8008.US01	ATL No. 10815-105014	US	Expired	61/028,142	12-Feb-08				
10815-8008.US02	ATL No. 10815-105014	US	Expired	61/152,064	12-Feb-09				
NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI									
10815-8009	ATL No. 10815-105024	US	Expired	61/183,847	03-Jun-09				
10815-8009.US01	ATL No. 10815-105040	US	Published	12/793,572	03-Jun-10	US-2010-0311820	09-Dec-10		
10815-8009.WO00	ATL No. 10815-105038 WO	PCT	Published	PCT/US2010/037319	03-Jun-10	WO 2010/141771	09-Dec-10		
10815-8009.US00	ATL No. 10815-105024	US	Expired	61/300,951	03-Feb-10				
CHARACTERIZATION OF OLIGONUCLEOTIDES CONJUGATES									
10815-8010	ATL No. 10815-105025	US	Pending	12/619,602	16-Nov-09				
10815-8010.WO00	ATL No. 10815-105026	PCT	Pending	PCT/US2009/064650	16-Nov-09				
METHOD FOR MANUFACTURING PEGYLATED OLIGONUCLEOTIDES									
10815-8011	ATL No. 10815-105039	US	Expired	61/327,622	23-Apr-10				
10815-8011.US00	NA	US	Pending	61/479,226	26-Apr-11				

Docket No.	Remarks	Country	Status	Application No.	Filing Date	Publication No.	Publication Date	Patent No.	Grant Date
NUCLEIC ACID MODULATORS OF PLATELET GP1BALPHA									
10815-8012	ATL No. 10815-105028	US	Pending	61/393,305	14-Oct-10				
NUCLEIC ACID MODULATORS OF CLEC-2									
10815-8013	ATL No. 10815-105034	US	Pending	61/393,191	14-Oct-10				
NUCLEIC MODULATORS OF GROWTH ARREST-SPECIFIC PROTEIN 6 (GAS6)									
10815-8014	ATL No. 10815-105035	US	Pending	61/393,803	15-Oct-10				
NUCLEIC ACID MODULATORS OF ALPHA2BETA1									
10815-8015	ATL No. 10815-105036	US	Pending	61/393,815	15-Oct-10				
PHASE 3 STUDY IDEA									
10815-8016	ATL No. 10815-105023	US	Abandoned	61/156,918	03-Mar-09				

EXHIBIT C

Trademarks

Except as set forth below, the Company has not registered or applied to register any other trademarks and/or service marks with the United States Patent and Trademark Office, but may have certain common law rights with respect to the marks “Regado” and/or other marks used in connection with the Company’s business. However, the Company makes no assurances that others have not used such marks prior to the Company’s use of such marks.

Serial Number	Registration Number	Mark
77/658,131	3711403	REGADO BIOSCIENCES
77/658,125	3711402	REGADO BIOSCIENCES
77/655,445	3711393	WE TAKE SCIENCE TO HEART
77/658,139		REGADO
77/658,108		REGADO
77/462,077		REGADO BIOSCIENCES THE ANTIDOTE CONTROL COMPANY
77/652,298		TAKING SCIENCE TO HEART

EXHIBIT D

Mask Works

None.